Context: Metabolites in the tricarboxylic acid (TCA) cycle are not only involved in energy metabolism but also play important roles in non-energy production activities.
Results: As compared with those with stable renal function (n = 271), participants who experienced progressive CKD (n = 116) had a lower level of urine citrate but significantly higher levels of lactate, fumarate, and malate levels at baseline. Both fumarate and malate predicted progressive CKD independent of traditional cardio-renal risk factors, including eGFR and albuminuria. Fumarate interacted with sex (P for interaction = 0.03) and independently predicted progressive CKD in male but not female participants. All these findings were reproducible in a validation study (case n = 96, control n = 402). Exploratory analysis suggested that fumarate might partially mediate the effect of oxidative stress on CKD progression.
Conclusions: Key TCA cycle metabolites, especially fumarate, may be involved in the pathophysiologic pathway independent of traditional cardio-renal risk factors, leading to CKD progression in patients with T2DM. (J Clin Endocrinol Metab 103: 4357-4364, 2018) C hronic kidney disease (CKD) progression (fast renal function decline) is the common pathway leading to end-stage renal disease and is emerging as an independent risk predictor for cardiovascular complications in patients with type 2 diabetes mellitus (T2DM) (1, 2) . However, the pathophysiologic mechanisms underpinning progressive CKD remain poorly understood.
Kidneys have a high mitochondria content and oxygen consumption to produce ATP for multiple energyconsuming functions, including biosynthesis, active waste removal, filtrate reabsorption, and regulation of electrolyte and acid-base balance (3) . Hence, disruption of mitochondrial homeostasis may reduce energy production and lead to loss of renal function (3) . In corollary, accumulating evidence has pointed to mitochondrial dysfunction as an important pathological mediator of diabetic kidney disease (DKD) (4) (5) (6) (7) .
Mitochondria have a broad range of functions. The tricarboxylic acid (TCA) cycle is the central hub of energy production in mitochondria and coordinates glucose, fatty acid, and amino acid metabolism (4, 8) . Therefore, it is reasonable to postulate that abnormality in TCA cycle metabolism may be a feature of mitochondrial dysfunction in DKD development and progression. In support of this, a recent cross-sectional study has shown that urine excretion of TCA cycle metabolites and renal expression of genes regulating these metabolites are reduced in patients with nondiabetic CKD (9) . It remains unknown whether these findings can be generalized to the diabetic population. On the other hand, TCA cycle metabolites are also involved in nonenergy production activities, such as biosynthesis (anaplerosis), maintenance of redox homeostasis, and regulation of inflammation (4, 8) . In this context, TCA cycle metabolites may be directly involved in pathophysiologic pathways independent of ATP production. For example, fumarate accumulation may activate expression of TGF-b, the master regulator of kidney fibrosis (10) . Also, it may play a role in regulation of adaptive immunity by inducing an epigenetic program (11) . A recent study in an animal model suggests that fumarate may be a mediator linking kidney intracellular oxidative stress and DKD pathogenesis (12) .
To our knowledge, the relationship between urine TCA cycle metabolites and progressive CKD has not been systematically studied in patients with T2DM. In the current work, we studied whether urine baseline levels of key TCA cycle metabolites (lactate, citrate, pyruvate, a-ketoglutaric acid, succinate, fumarate, and malate) predict progressive CKD independent of traditional cardio-renal risk factors, especially baseline glomerular filtration function and albuminuria, in participants with T2DM.
Participants and methods
We included two independent nested case-control studies in the current work to examine the association of urine TCA cycle metabolites with progressive CKD. Participants were selected and included according to case (progressive CKD) and control (nonprogressor with stable renal function) definitions as described later and in Fig. 1 .
Discovery study
The assembly of the cohort in which the discovery study was nested has been described elsewhere (13) . Briefly, 2337 outpatient participants with T2DM were recruited consecutively between 2004 and 2013 in a regional hospital in Singapore and were followed during their usual clinic visits (censored by March 2014 for the current study). Participants with a baseline estimated glomerular filtration rate (eGFR) $30 mL/min/ 1.73 m 2 and a minimum of three eGFR readings during followup were considered as potential candidates for inclusion. eGFR trajectories were calculated by linear regression by which eGFR readings were regressed onto time of follow-up (years). The coefficient of time was taken as annual eGFR change.
Progressive CKD was defined as an eGFR decline of $5 mL/min/1.73 m 2 per year in the follow-up period (1, 14) . On the assumption that patients with T2DM with comorbidities may have an eGFR decline of 1 to 2 mL/min/1.73 m 2 per year (14, 15) , participants with an eGFR decline of ,2 mL/min/1.73 m 2 per year were defined as nonprogressor control subjects. Because a positive eGFR trajectory was also associated with adverse clinical outcomes (15, 16) , we excluded participants with an eGFR increase of .2 mL/min/1.73 m 2 per year from the control group. Participant eGFR follow-up duration in the discovery cohort ranged between 1 and 9 years. We reasoned that the longer the follow-up, the more likely would we be able to ascertain the stability of renal function. Therefore, we considered only those with $5 year eGFR follow-up as candidates of nonprogressor controls in the discovery study.
Validation study
The validation study was nested in the Singapore study of macro-angiopathy and microvascular reactivity in type 2 diabetes (SMART2D) cohort (17) . In brief, 2057 participants (21 years and older) with T2DM were recruited consecutively from a regional hospital and a community primary care facility in Singapore between August 2011 to March 2014. Three years after enrolment, participants were recalled for the planned follow-up study. By May 2016, 970 participants had completed the 3-year revisit, and those with eGFR $30 mL/min/1.73 m 2 at baseline (n = 936) were considered as potential candidates for the current study. Annual change in renal filtration function was estimated as the difference between baseline and follow-up eGFR divided by follow-up duration [median, 3.1; interquartile range (IQR), 3.0 to 3.2 years]. The rate of annual eGFR change for definition of cases (progressive CKD) and controls (stable renal function) in the validation study was the same as that in the discovery study.
The current studies were conducted in compliance with principles laid out by the Helsinki Declaration. The discovery and validation studies have been approved by the Singapore National Health Care Group Domain Specific Review Board. Written consent was obtained from each participant.
Quantification of urine key TCA cycle metabolites by gas chromatography-mass spectrometry Morning spot urine specimens were collected after overnight fast and stored at 4°C for ,1 hour before being aliquoted and transferred to 280°C. Samples used for the current studies did not undergo repeated freeze and thaw. Seven key TCA cycle metabolites (lactate, pyruvate, citrate, a-ketoglutaric acid, succinate, fumarate, and malate) were quantified at the Metabolomics Facility of the Duke-NUS Medical School of Singapore. Urine samples with creatinine concentrations .4 mM were diluted to 4 mM creatinine by ultrapure water before metabolite extraction. Neat urine samples with creatinine concentration ,4 mM (;10% of all samples) were used for extraction, but final concentrations of metabolites were normalized to 4 mM creatinine level by ratio.
Stable isotope internal standards were spiked into each study sample. Metabolites were extracted by ethyl acetate after adding ethoxyamine to complete ethoxymation of ketoacids. The extractant was dried and derivatized with N, O-Bis(trimethylsilyl)trifluoroacetamide to form trimethylsilyl derivatives. The trimethylsilyl derivatives were separated on a VF-1 mass spectrometry (MS) column on an HP 7890A gas chromatography (GC) system and quantified by selected ion monitoring on a 5975C mass spectrometer (Agilent Technologies). MS data were analyzed on a Mass Hunter Workstation vB.06.00 (Agilent Technologies), and quantification was based on stable isotope dilution. Nearly all (99.5%) of the metabolite readings were within the calibration curves.
An aliquot from each study sample was pooled as a quality control (QC) sample for the discovery and validation studies. The QC sample was injected after every eighth study sample. The relative SD of QC, which might indicate stability of metabolite responses on MS, was ,5% for all seven metabolites in both the discovery and validation studies. To account for runorder effects, samples were coded and randomized before sample preparation and GC-MS assays.
Clinical and biochemical variables
Baseline clinical data collection and biochemical measurements have been described elsewhere (13, 17) . In brief, all biochemical measurements were performed in the same clinical referral laboratory, which has been accredited by the College of American Pathologists. HbA1c was quantified by the immunoturbidimetric method (Cobas Integra 800 Analyzer; Roche, Basel, Switzerland) in the discovery study and measured by a point-of-care immunoassay analyzer (DCA Vantage Analyzer; Siemens, Munchen, Germany) in the validation study. Triacylglycerol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol levels were measured by enzymatic methods. Urine albumin was quantified by a solidphase competitive chemiluminescent immunoassay (Immulite; DPC, Gwynedd, UK), and albuminuria level was presented as albumin-to-creatinine ratio (ACR, mg/g). The urine oxidative stress biomarker 8-OH-deoxyguanosine (8-OH-dG) was measured by a competitive quantitative ELISA kit (Abcam, Cambridge, MA). 8-OH-dG level was normalized to urine creatinine concentration before data analysis. Both intra-and interassay coefficients of variations were ,5%. Creatinine was quantified by an enzymatic method, which was traceable to isotope dilution MS reference. All eGFR readings in the current studies were estimated by the Chronic Kidney DiseaseEpidemiology Collaboration formula. For the discovery study, eGFR was measured at the date of recruitment, and eGFR readings at the follow-up study were extracted from electronic medical records that were measured by the same clinical laboratory.
Statistical analysis
Data were presented as mean 6 SD, as median (IQR), or as percentage where appropriate. Serum triacylglycerol, urine ACR, and TCA cycle metabolite levels were natural logarithmically transformed due to skewed distributions. Betweengroup differences in baseline clinical and biochemical variables were compared by Student t tests or x 2 tests. Multivariable linear regression models were fitted to examine which clinical and biochemical variables were independently associated with urine metabolite levels at the cross-sectional level. Natural logtransformed individual metabolite was the dependent variable, and clinical and biochemical variables were entered as independent variables.
Multivariable logistic regression models were applied to study which urine TCA cycle metabolites at baseline were associated with progressive CKD. Binary outcome of CKD progression (yes or no) was the dependent variable, urine metabolite level (natural log-transformed) was entered as independent variable, and potential clinical and biochemical confounders were entered as covariates. We entered products of sex 3 natural log-transformed fumarate or malate as covariate terms, respectively, in logistic regression models to examine the interactions between fumarate or malate and sex in their associations with progressive CKD.
The Sobel test was used to study whether fumarate mediated the effect of oxidative stress on CKD progression. Baron and Kenney procedure was applied to estimate proportion of mediated effect (18, 19) .
Statistical analyses were performed by SPSS (version 22; IBM, Armonk, NY). We applied Bonferroni correction to control potential type I errors in multiple comparisons of seven metabolites in discovery study (0.05/7 = 0.007). Significance for interaction term was specified as P , 0.05 for the discovery study and P , 0.1 for the validation study. A two-sided P , 0.05 level was considered to be statistically significant for all other analyses.
Results

Participant characteristics
Baseline characteristics of participants in the discovery and validation studies were comparable (Table 1 ). In the discovery study, the number of eGFR measurements was 1.4 (IQR, 1.2 to 2.2) per year. Participants who experienced progressive CKD were followed for 4.4 6 1.6 years, and the slope of eGFR decline was 27.8 (IQR, 211.1 to 26.2) mL/min/1.73 m 2 per year. In a validation study, the estimated rate of eGFR decline was 29.4 (IQR, 215.1 to 27.5) mL/min/1.73 m 2 per year among participants with progressive CKD.
Participants with progressive CKD had higher levels of HbA1c and higher systolic blood pressure as compared with those with stable renal function ( Table 1) . As expected, they had a lower eGFR and a higher ACR level at baseline; both variables were established risk predictors for progressive CKD (20) . In addition, participants with progressive CKD were more likely to be of Malay ethnicity and to be on reninangiotensin system blocker and insulin treatments. There were no significant between-group differences in age, smoking status, and body mass index (BMI).
Baseline levels of urine TCA cycle metabolites in participants with progressive CKD and those with stable renal function Four urine metabolites differed significantly between CKD progressors and nonprogressor control subjects in the discovery study (P , Bonferroni-corrected threshold 0.05/7 = 0.007) ( Table 2 ). All between-group differences in these four metabolites could be validated (P , 0.05). Specifically, urine citrate level was significantly lower, whereas lactate, fumarate, and malate levels were significantly higher, in participants with progressive CKD as compared with controls with stable renal function. In multivariable linear regression models, urine citrate level was independently associated with eGFR, and lactate level was independently associated with HbA1c and ACR after adjustment for other clinical and biochemical covariates. Urine fumarate and malate levels were highly correlated (Pearson r = 0.96 and 0.94; Supplemental Fig. 1) , and both were independently associated with sex, HbA1c, urine, and ACR but not eGFR in both the discovery and validation studies (Supplemental Table 1 ).
Baseline urine fumarate and malate levels predicted progressive CKD independent of traditional cardio-renal risk factors
We studied which urine metabolites might predict progressive CKD independent of traditional cardio-renal risk factors, especially baseline eGFR and ACR (20) . Urine citrate level predicted progressive CKD after accounting for baseline clinical, demographic, and cardiometabolic risk factors; BMI; HbA1c; and systolic blood pressure in both the discovery and validation studies. However, the magnitude of its association with progressive CKD was attenuated after further adjustment for eGFR and ACR in the validation study (Model 2, Table 3 ). Urine lactate level predicted progressive CKD after adjustment for demographic and cardiometabolic risk factors in both studies (Model 1, Table 3 ). Similar to the finding with urine citrate, its association with progressive CKD was weakened after further adjustment for baseline eGFR and ACR.
Urine fumarate and malate levels predicted progressive CKD independent of clinical and cardiometabolic risk factors (Model 1, Table 3 ). The associations remained statistically significant after further adjustment for baseline eGFR and ACR, although the magnitudes of the associations were slightly reduced (Model 2, Table 3 ). Hence, we focused on urine fumarate and malate in the following analyses.
Sex modulated the association of urine fumarate with progressive CKD Sex was independently associated with urine fumarate and malate levels in both the discovery and validation studies (Supplemental Table 1 ). This prompted us to examine whether sex modulated the associations of fumarate/malate with progressive CKD. We found that fumarate interacted with sex in its association with progressive CKD in both the discovery and validation studies (P for interaction = 0.02 and 0.09, respectively). The multiplicative interaction term remained significant after further adjustment for age and ethnicity. Urine malate also interacted with sex in its association with CKD progression in the discovery study (P for interaction = 0.03). However, the multiplicative interaction term was not statistically significant in the validation study (P for interaction = 0.32).
Further analysis after stratification by sex showed that baseline urine fumarate level independently predicted CKD progression in male but not female participants. The independent association of urine fumarate with progressive CKD in male participants remained statistically significant after adjustment for clinical and cardiometabolic risk factors, baseline eGFR, ACR, and lipid profile (Table 4) .
Urine fumarate might partially mediate the effect of oxidative stress on CKD progression A previous study in an animal model suggested that fumarate might play an important role in DKD pathogenesis by mediating the effects of oxidative stress (12). Variables reaching statistical significance in the discovery and validation substudies are shown in boldface. a Student t tests.
As an exploratory study, we measured urine level of 8-OH-dG, an established oxidative marker, to examine the relationships among oxidative stress, urine fumarate, and progressive CKD in participants of the discovery study. Similar to our observation with fumarate, baseline urine 8-OH-dG (natural log-transformed) predicted progressive CKD in male (OR, 3.55; 95% CI, 1.74 to 7.24; P , 0.0001) but not female (OR, 1.29; 95% CI, 0.77 to 2.15; P = 0.33) participants. Mediation analysis by Sobel test showed that urine fumarate partially mediated the association of urine 8-OH-dG with CKD progression (T = 2.75, P = 0.006) in male participants. Further analysis showed that Baron and Kenney proportion of mediated effect was 17.0% (18, 19) .
Sensitivity analysis
Urine sample storage time varied between 1 and 9 years in the discovery study. We examined whether sample storage time affected the association of urine metabolites with progressive CKD. In a bivariate analysis, none of the seven urine metabolite concentrations was significantly correlated with storage time. Adding storage time as a covariate in logistic regression models did not materially alter the outcomes. Excluding six participants with ,2 years of follow-up in the discovery study did not materially change the outcomes.
Discussion
In two independent nested case-control studies, we found that urine lactate, citrate, fumarate, and malate levels differed significantly between patients with T2DM with progressive CKD and those with stable renal function. Baseline urine fumarate and malate levels predicted progressive CKD independent of traditional cardio-renal risk factors, including eGFR and albuminuria. Furthermore, we found that urine fumarate interacted with sex in its association with progressive CKD. These data added evidence to support that key TCA cycle metabolites, especially fumarate, may be involved in pathophysiologic pathways underpinning progressive CKD in individuals with type 2 diabetes.
Although our results show the independent association of urine fumarate with a high risk for progressive CKD in individuals with T2DM, the biochemical mechanisms remain to be elucidated. As one of the key metabolites in the TCA cycle, fumarate plays important roles in other biological pathways, such as redox homeostasis, matrix gene expression, and expression of hypoxia-inducible factor 1a and TGF-b (12, 21, 22) . Hypoxia-inducible factor 1a activation leads to "anaerobic" glycolysis and lactate production via enhanced lactate dehydrogenase and suppresses mitochondrial oxidative phosphorylation (pseudohypoxia), and TGF-b has been considered as the master regulator of kidney fibrosis (10) . Emerging data showed that fumarate might induce an epigenetic program by regulating histone methylation, which could in part explain the "metabolic memory" phenomenon (11, 23) . Given the biological plausibility and the robust association of urine fumarate level with progressive CKD in the current study, we hypothesize that fumarate may be causally involved in pathophysiologic pathways underpinning CKD progression in T2D. Future clinical and animal studies are warranted to test this hypothesis.
A lower urine excretion of citrate in nondiabetic CKD has been observed by Hallan et al. (9) in an early crosssectional study. The inverse association of urine citrate level with eGFR in the current study is consistent with earlier reports (9, 24) . Urine citrate has been considered as a marker of acid production in the kidney. The reduction in urine citrate at a lower eGFR level may indicate a lower rate of organic anion production because citrate synthase is often considered as the rate-limiting node of the TCA cycle (24, 25) . On the other hand, a lower urine citrate level may suggest increased tubular uptake and metabolism of organic anions as a compensation to normalize acid-base balance in the setting of reduced tubular function in individuals with a high risk for CKD progression (26) .
Our results show that urine lactate level in participants with progressive CKD was higher than that in those with stable renal function. The higher urine lactate level may result from increased anaerobic glycolysis (i.e., a shift to Warburg metabolism). Hypoxia persists in diabetic kidneys presumably due to increased oxygen utilization as a result of reduced metabolic efficiency coupled with increased sodium and glucose reabsorption in the proximal tubule (27, 28 ). Therefore, increased lactate level may imply a state of mitochondrial stress in diabetic kidneys in those with high risk for progressive CKD (27) .
The independent association of citrate with progressive CKD, as well the interaction of malate with sex in its association with CKD progression, are not validated in our current work. However, these data should be interpreted with caution. Despite similar clinical profiles (Table 1) and consistent between-group changes in urine TCA cycle metabolites (Table 2) , discovery and validation studies are different in renal function follow-up. The former has a longer follow-up with multiple eGFR readings to calculate the trajectory of eGFR progression, whereas eGFR changes in our validation study were estimated based on two eGFR readings 3 years apart. The inaccurate estimation of annual eGFR change in validation study may result in larger random errors and false-negative outcomes (type 2 error). Therefore, these nonreproducible outcomes deserve further study from other independent cohorts.
Our data should be interpreted within the context of the study's strengths and weaknesses. The criterion for CKD progression adopted in the current work has important clinical implications (1, 14) . We used two studies with participants selected from two independent cohorts in the current work, and the majority of the findings are reproducible. Also, quantification of TCA cycle metabolites by GC-MS is technically more robust than biochemical assays. Nevertheless, several weaknesses should be highlighted. First, estimation of annual eGFR change in the validation study is based on two time-point readings. The inaccurate estimation of renal trajectory may result in false-null outcomes. Second, data of some potential confounders, such as physical activity, history of cardiovascular diseases, and details of nondiabetic medications, were not collected in the two cohorts. Therefore, residual confounding exists in our analysis. Third, mitochondria have several functions. We only profiled seven key TCA cycle metabolites. Future targeted and untargeted metabolomics studies are warranted to gain a broader perspective on the role of mitochondrial dysfunction in progressive CKD in patients with T2DM. Fourth, due to the nature of the study, we were unable to elucidate the cellular and molecular mechanisms underlying the alterations in TCA cycle metabolites in participants at high risk for progressive CKD. Unlike the early study in nondiabetic CKD (9), we did not have data on the expression of genes regulating TCA-cycle metabolites in kidney tissue. The latter may shed light on the mechanism of alterations in urine TCA cycle metabolites in patients with T2DM and progressive CKD. In light of the discussions herein, our current work should be taken as hypothesis generation, instead of causality inference, to prompt more mechanistic studies in the future.
In summary, our data suggest that TCA cycle metabolites, especially fumarate, may play a role in the pathophysiologic pathway leading to CKD progression. Further in-depth study of TCA cycle-related metabolisms may shed light on new biochemistry underpinning DKD development and progression in patients with T2DM. 
